my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
09-08-2012: Celtic Pharma Holdings Advisors LLP announced that Novacta Biosystems Limited has completed a Phase I clinical trial of NVB302, the Company’s orally administered treatment for Clostridium difficile infection (“CDI”).
Both single ascending dose and multiple ascending dose studies in a total of 64 healthy volunteers revealed NVB302 to be safe and well-tolerated at all doses tested. Consistent with data from preclinical models, there was negligible systemic absorption of the drug and high concentrations were recovered in the faeces.
Developed with support from a Wellcome Trust Strategic Award, NVB302 is a member of a compound class known as Type B lantibiotics. It has properties that make it ideally suited as a new treatment for CDI, including excellent activity against all strains of C. difficile tested whilst having minimal activity against the predominantly Gram-negative natural flora of the gut. NVB302 has exhibited promising activity in both in vitro and in vivo models of CDI.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Celtic Pharma Holdings Advisors LLP announced that Novacta Biosystems Limited has completed a Phase I clinical trial of NVB302, the Company’s orally administered treatment for Clostridium difficile infection (“CDI”).Both single ascending dose and multiple ascending dose studies in a total o ... more
DSM to manufacture C. difficile compound for Novacta Biosystems
DSM BioSolutions announced that it has entered into an agreement with Novacta Biosystems Limited for the process development and cGMP production of its C. difficile molecule, a new class of lantibiotic compounds. DSM has successfully completed the process development and commenced cGMP-man ... more
Novacta therapeutics and Oxygen Healthcare announce a multi FTE medicinal chemistry collaboration
Novacta Therapeutics and O2h announced a multi FTE chemistry collaboration to support their internal drug discovery efforts. This is the third successive collaboration over the last three years. “Following two very successful projects, we are excited to enter a third collaboration that co ... more
Novacta is a UK-based biotechnology company that specialises in the discovery and development of potential treatments for infectious diseases using a class of naturally occurring compounds called lantibiotics Novacta's proprietary, patented technologies are in the fields of 'pathway engine ... more
Celtic Pharma Holdings Advisors LLP announced that Novacta Biosystems Limited has completed a Phase I clinical trial of NVB302, the Company’s orally administered treatment for Clostridium difficile infection (“CDI”).Both single ascending dose and multiple ascending dose studies in a total o ... more
New International Pharmaceutical Company Pro Bono Bio
Pro Bono Bio™, a new international pharmaceutical company, is the result of a three year Anglo/Russian project, developed by Celtic Pharma Holdings in London. Pro Bono Bio has ambitious growth targets that will allow it to support a unique humanitarian mission. Pro Bono Bio combines global ... more
Celtic Therapeutics and Bellus Health initiate confirmatory Phase III clinical study for KIACTA
BELLUS Health Inc. and Celtic Therapeutics announced that a global confirmatory phase III clinical study was initiated on December 14, 2010 for KIACTA™ (eprodisate). KIACTA™ is a drug candidate being developed for the treatment of AA amyloidosis, a life-threatening orphan disease that occur ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
